There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
19h
Zacks Investment Research on MSNSAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyShares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results